The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $306,872 Project Grant (CFDA 93.846) to Vivreon Biosciences LLC, a biotechnology company in San Diego, CA. The funding will support the development of a novel small molecule therapeutic targeting the ORAI1 calcium channel, which has been validated as a therapeutic target for Duchenne muscular dystrophy (DMD) and other dystrophinopathies. The grant efforts will assess the toxicity profile and efficacy of the candidate compound in preserving muscle force generation in a DMD animal model, with the goal of a 50% improvement in muscle force production. Achieving these milestones will position the therapeutic as a promising candidate for further development as a treatment for dystrophinopathies. The award period is from September 1, 2024 to July 31, 2025.
Generated 3/4/25, 7:16 AM